Roche Reports Major Phase III Success for Multiple Sclerosis Drug Fenebrutinib
The global healthcare company Roche has announced a promising advance in the treatment of multiple sclerosis (MS). Its experimental oral drug Fenebrutinib has shown major Phase III trial success, targeting a market that has long awaited new therapies. This update not only matters for patients but also has implications for investors and those doing stock…